Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18662321 | 0.88 | FAAH (0.53) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL18662344 | 0.83 | FAAH (0.53) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL18662329 | 0.82 | FAAH (0.54) | FAAHNPC1RAB9AERN1 | |
| SCHEMBL18662340 | 0.80 | FAAH (0.54) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL3024393 | 0.77 | FAAH (0.51) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL15663188 | 0.77 | MGLL (0.47) | FAAHMGLLALDH1A1KDM4EMEN1 | |
| SCHEMBL5092650 | 0.76 | ALDH1A1 (0.45) | FAAHMGLLALDH1A1KDM4EMEN1 | |
| SCHEMBL27981323 | 0.76 | LMNA (0.51) | FAAHMGLLALDH1A1KDM4EMEN1 | |
| SCHEMBL6215102 | 0.75 | KDM4E (0.68) | ALDH1A1KDM4EMEN1NPC1MITF | |
| SCHEMBL1345987 | 0.74 | HRH3 (0.62) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101819-B1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | HARVARD COLLEGE (US) | 2013-01-09 | — | — | EP | claimed |
| WO-2024225481-A1 | AGENT FOR IMPROVING THERAPEUTIC RESPONSIVENESS IN CANCER IMMUNOTHERAPY WITH PD-1 INHIBITOR OR PD-L1 INHIBITOR | 国立大学法人京都大学 | 2024-10-31 | — | — | WO | disclosed |
| EP-3443956-A1 | A COMPOUND INCREASING ENDOCANNABINOIDS CONCENTRATION IN A SUBJECT FOR USE FOR PREVENTING AND/OR TREATING A SOCIAL BEHAVIOR DISORDER | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-02-20 | — | — | EP | disclosed |
| US-8778643-B2 | Methods for increasing lipid levels and producing triacylglycerols in algae | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060167075-A1 | Modulators of FAAH | IRONWOOD PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | FAAH 1060/4885TRPA1 1796/4885EPHX2 862/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | FAAH 996/4885TRPA1 1178/4885EPHX2 2900/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | FAAH 1716/4885TRPA1 4433/4885EPHX2 2118/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | FAAH 1051/4885TRPA1 3561/4885EPHX2 994/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | FAAH 367/4885TRPA1 1682/4885EPHX2 1005/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | FAAH 739/4885TRPA1 1284/4885EPHX2 1948/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | FAAH 1060/4885TRPA1 1796/4885EPHX2 862/4885 |
| US-20060167075-A1 | Modulators of FAAH | FAAH, FAAH2, HCRTR2 | FAAH 1/4885TRPA1 1493/4885EPHX2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.